Announcements
Latest Funding Includes Support for Innovative Clinical Trial
07/11/2017
The Alzheimer’s Drug Discovery Foundation (ADDF) announces four new grants, including support for an innovative clinical trial, two novel drug programs, and a biomarker for CTE.
2016 Annual Report Released
06/29/2017
The 2016 Annual Report, titled “From Idea to Impact,” highlights the enormous progress the ADDF has made toward finding effective treatments for Alzheimer’s disease.
ADDF and Science Exchange Launch ADDF ACCESS to Advance Research
06/07/2017
New “CRO Finder” Connects Scientists with Specialized Resources
$2.6 Million in New Grants Spurs Innovation
05/15/2017
We announce 10 new grants totaling over $2.6 million to drive promising new approaches to treating and diagnosing Alzheimer’s and related dementias.
Tad Smith & Sotheby’s Honored at Connoisseur’s Dinner
05/11/2017
11th annual gala raises $2.5 million for lifesaving Alzheimer's treatments
Author Sally Quinn Honored at Our Great Ladies Luncheon, Hosted by Judy Woodruff
04/27/2017
We raised over $350,000 for life-saving research at our Seventh Annual Great Ladies Luncheon & Fashion Show at the Ritz-Carlton Washington, D.C., which honored author Sally for her work in the fight against Alzheimer’s.
ADDF Invests $300,000 to Support Phase 2 Clinical Trial of Epigenetic Therapy
04/24/2017
A new investment of $300,000 in Oryzon Genomics continues our support of its groundbreaking epigenetic drug ORY-2001.
ADDF-Funded Scientists Discover Two Repurposed Drugs With Promise for Alzheimer’s and FTD
04/20/2017
A team of scientists from the Medical Research Council (MRC) in the UK have found two drugs, which block brain cell death and prevent neurodegeneration in preclinical studies. Their findings were published today in Brain.
ADDF Funding Advances M3 Biotechnology Toward Clinical Trials
04/13/2017
Our new investment in M3 Biotechnology is advancing its drug program toward clinical trials
$4 Million in New Grants Support Several First-in-Class Dementia Treatments
03/07/2017
We recently awarded eight new grants totaling over $4 million to advance treatments for Alzheimer’s and related dementias. Several of the awards support new approaches to treating these diseases.